TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioAtla ( (BCAB) ) has issued an update.
On November 20, 2025, BioAtla, Inc. entered into Pre-Paid Advance Agreements with YA II PN, Ltd., Anson Investments Master Fund LP, and Anson East Master Fund LP, securing a $7.5 million advance. The agreement allows for repayment in cash or conversion into common stock shares, with specific pricing conditions. Additionally, BioAtla entered into a Standby Equity Purchase Agreement with Yorkville, enabling the sale of up to $15 million in common stock over 36 months. These financial arrangements are designed to provide BioAtla with capital flexibility, subject to customary conditions and limitations, potentially impacting its market operations and stakeholder interests.
The most recent analyst rating on (BCAB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.
Spark’s Take on BCAB Stock
According to Spark, TipRanks’ AI Analyst, BCAB is a Underperform.
BioAtla’s stock faces significant challenges, primarily due to its financial position, characterized by a lack of revenue and high cash burn. Despite promising clinical progress and strategic efforts to manage cash, the company’s valuation and technical indicators reflect a bearish outlook. The overall score reflects these substantial risks, with some potential upside from clinical developments.
To see Spark’s full report on BCAB stock, click here.
More about BioAtla
Average Trading Volume: 1,338,576
Technical Sentiment Signal: Buy
Current Market Cap: $68.2M
Learn more about BCAB stock on TipRanks’ Stock Analysis page.